Research & Development in the Pharmaceutical Industry
Seiten
2009
Nova Science Publishers Inc (Verlag)
978-1-60692-971-1 (ISBN)
Nova Science Publishers Inc (Verlag)
978-1-60692-971-1 (ISBN)
Reviews basic facts about the drug industry's spending on research and development (R and D) and its output of drugs. This title examines issues relating to the costs of R and D, the federal government's role in pharmaceutical research, and the performance of the pharmaceutical industry in developing innovative drugs.
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study -- prepared at the request of the Senate Majority Leader -- reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D.
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study -- prepared at the request of the Senate Majority Leader -- reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D.
Preface; Research and Development in the Pharmaceutical Industry; New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts; Index.
| Erscheint lt. Verlag | 10.2.2009 |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 230 x 155 mm |
| Gewicht | 410 g |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Technik | |
| ISBN-10 | 1-60692-971-2 / 1606929712 |
| ISBN-13 | 978-1-60692-971-1 / 9781606929711 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Pharmaceuticals, Diagnostics, Medical Devices
Buch | Hardcover (2023)
Wiley-VCH (Verlag)
CHF 109,95
lernfeldorientiert und fächerübergreifend 2. Schuljahr
Buch (2024)
Deutscher Apotheker Verlag
CHF 41,70
